Somatostatin Receptor 2 Expression Determined by Immunohistochemistry in Cold Thyroid Nodules Exceeds That of Hot Thyroid Nodules, Papillary Thyroid Carcinoma, and Graves' Disease
- 1 May 2010
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 20 (5) , 505-511
Abstract
Background: There is a plethora of partly contradictory reports on somatostatin receptor (SSTR) expression in thyroid tumors. Therefore, our goal was to systematically determine SSTR2 expression in benign cold thyroid nodules (CNs), hot thyroid nodules (HNs), papillary carcinomas (PCs), and Graves' disease (GD) in comparison with intraindividual control tissues by means of immunohistochemistry. Methods: Tissue sections from 19 HNs, 10 CNs, 17 PCs and their surrounding tissues, and 8 GD thyroids were immunostained for SSTR2. Membranous SSTR2 staining was quantitated by evaluating 10 high-power fields (HPFs) systematically distributed along the largest diameter of the tissue section. Results: The area covered by thyroid epithelial cells in 10 HPFs expressed as median (in mm2) was 0.53 for CNs, 0.44 for HNs, 1.5 for PCs, 1.3 for GD, and 0.3 for the surrounding tissues. The SSTR2 staining density determined by dividing the area of SSTR2 positively stained thyroid epithelial cells (in mm2) by the area of all thyroid epithelial cells (in mm2) in 10 HPFs was 0.1662 for CNs, 0.0204 for HNs, 0.0369 for PCs, and 0.0386 for GD. Conclusions: SSTR2 expression is inhomogeneous in thyroid disease, with the highest density detected in CNs. It remains to be determined whether this finding could be of pathophysiologic or therapeutic relevance. The high SSTR2 density in CNs should be considered in the interpretation of SSTR scintigraphy-positive findings.Keywords
This publication has 33 references indexed in Scilit:
- Relative Quantification of Indium-111 Pentetreotide and Gallium-68 DOTATOC Uptake in the Thyroid Gland and Association with Thyroid PathologiesThyroid®, 2009
- 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphyRevista Española de Medicina Nuclear, 2006
- 99mTc-Depreotide Scintigraphy Versus18F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2006
- Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroidBritish Journal of Cancer, 1999
- Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptakeEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Uptake of In-111 Pentetreotide by Normally Functioning Nodular GoitersClinical Nuclear Medicine, 1997
- Somatostatin receptor scintigraphy in medullary thyroid carcinomaBritish Journal of Surgery, 1997
- Somatostatin Receptor Expression in the Thyroid Demonstrated with 111In-Octreotide ScintigraphyNuklearmedizin-Nuclear Medicine, 1995
- [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?The Journal of Clinical Endocrinology & Metabolism, 1994
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993